Midodrine

Cross-source consensus on Midodrine from 1 sources and 5 claims.

1 sources · 5 claims

Uses

Midodrine is an oral alpha-1 adrenergic agonist approved by the FDA for symptomatic orthostatic hypotension. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
Midodrine stimulates alpha-1 receptors in venous and arterial vasculature, causing vasoconstriction and increasing systolic blood pressure. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
Midodrine has approximately 93% enteral bioavailability, begins acting within 1 hour, and lasts 3 to 4 hours. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
Enteral midodrine is proposed to address sepsis-associated hypotension without invasive vascular access. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
In a Mayo Clinic observational cohort, off-label midodrine use was associated with improved blood pressure and reduced vasopressor support measures. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial